Souhaitez-vous accéder aux communiqués récents ?

ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from...

First patient dosed in Australia where 3 clinical trial sites have been activated.The trial will enrol advanced colorectal cancer patients whose cancer expresses the cancer stem cell marker LGR5, and...

LGR5 is expressed, both in vitro and in vivo, by numerous human cancers, including colorectal, ovarian, gastric, brain, and pancreatic cancer. LGR5-targeting CAR-T cells effectively kill...

ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced the appointment of Michael S. Wyzga, M.B.A., and Remus Vezan...

ADELAIDE, Australia, May 24, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced that the management team will participate in the three upcoming...

First in human, multicenter, open label, Phase 1/2a dose escalation and expansion study to determine the safety of and overall best response to CNA3103 in subjects with mCRCPhase 1 segment of the...

Preclinical data demonstrates that LGR5-targeting CAR-T therapy has high potential as an effective therapeutic for human colorectal cancer.LGR5-targeting CAR-T cells effectively kill LGR5-expressing...

Preclinical evidence shows that LGR5 targeted CAR-T cells are able to kill ovarian cancer cells and to reduce ovarian cancer tumor burden in animal modelsThe data suggests that LGR5 CAR-T cells have...

Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103On track to commence patient enrollment during the first half 2023 ADELAIDE, Australia , Jan. 23,...

HIGHLIGHTS Files its first IND application for a CAR-T cell therapy targeting a solid cancer. The IND application is directed at a first-in-human Phase 1/2a clinical trial in advanced colorectal...